Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- JIRA Aims at Introducing Medical Devices Law
January 29, 2001
- Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
- Olympus Aims at \100 Bil. Sales with Genomic Healthcare
January 29, 2001
- In vitro Fertilization Using Sperm, Ova from Third Parties to Be Approved
January 29, 2001
- Economy, Trade, Industry Ministry to Help Handicapped Persons Obtain Access to Internet
January 29, 2001
- Government to Refuse Disclosure of AIDS Study Group's Minutes
January 29, 2001
- NPO to Hold Fair to Help Elderly Participate in Social Activities
January 29, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 29, 2001
- Aiming at \100 Billion Sales in 2005: Mr Ogawa of Nippon Roche
January 29, 2001
- Most Patients Satisfied with Administration Method for Zithromac
January 29, 2001
- Schering-Plough, Shionogi to Comarket Antiallergic Claritin
January 29, 2001
- Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
- Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
- Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
- Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
- Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
- Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
- WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
- Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
- BI Establishes Virtual Research Institute of Aging
January 29, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…